Business/Financial Results (Form 8-K)

On October 14, 2025, Spyre Therapeutics, Inc. (the "Company") announced that while the Company has not finalized its full financial results for the quarter ended September 30, 2025, the Company expects to report that it had approximately $486.2 million of cash, cash equivalents and marketable securities as of September 30, 2025.

This amount is preliminary, has not been audited and is subject to completion of the Company's financial closing procedures. The Company's independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to this preliminary information and, accordingly, does not express an opinion or any other form of assurance with respect thereto. Consequently, this amount may differ materially from the amount that will be reflected in the Company's unaudited consolidated balance sheet as of September 30, 2025.